Young Man’s Heart Attack Linked to Cannabis Use — But One Case Can’t Prove Causation
Young Man’s Heart Attack Linked to Cannabis Use — But One Case Can’t Prove Causation
A detailed 2025 case report describes Wellens syndrome in a 30-year-old chronic cannabis and tobacco user, presenting thorough clinical imaging and successful coronary intervention while leaving the question of cannabis-specific causation entirely unresolved due to multiple uncontrolled confounders.
Why This Matters
Acute coronary syndrome in adults under 40 is uncommon but increasingly recognized, and clinicians are encountering more patients who use cannabis regularly and present with chest pain. Wellens syndrome, a specific ECG pattern signaling critical proximal left anterior descending artery stenosis, carries high risk of anterior wall myocardial infarction if missed. As cannabis use rises across demographics, any signal linking it to cardiovascular events in young people demands serious clinical attention. At the same time, premature causal claims risk distorting clinical decision-making and public health messaging before the evidence base is mature enough to support them.
Clinical Summary
Cannabis use has been associated with increased cardiovascular risk in several observational and epidemiological studies, with proposed mechanisms including CB1 receptor-mediated vasoconstriction, platelet activation, and promotion of a prothrombotic state. This 2025 case report, published in JACC: Case Reports by Boukili et al., describes a 30-year-old male with a 15-year history of smoking mixed cannabis-tobacco cigarettes who presented with progressive left-sided chest pain, diaphoresis, and dyspnea. His initial ECG showed biphasic T waves in leads V2 through V3, the hallmark of Wellens syndrome Type A, which evolved within 30 minutes to ST elevation in V2 through V4. The clinical team proceeded with emergent coronary angiography, which revealed 80% ostial-proximal LAD stenosis. Optical coherence tomography further demonstrated lipid-rich plaque with superimposed acute red thrombus.
The patient underwent successful OCT-guided percutaneous coronary intervention with a drug-eluting stent, achieving TIMI 3 flow. His echocardiogram showed borderline left ventricular ejection fraction at 53% with apical hypokinesis and grade I diastolic dysfunction. Critically, however, the patient had concurrent 15-year tobacco exposure, severely elevated blood pressure at presentation of 170/140 mmHg, thrombocytosis, and leukocytosis. None of these confounders were adequately separated from the cannabis exposure in the authors’ analysis. No cannabis-specific biomarkers such as endocannabinoid levels or CB1 receptor activity were measured. The authors themselves acknowledge that larger epidemiological studies are needed, yet their title frames the event as “cannabis-induced,” a causal claim that exceeds what any single case report can support.
Dr. Caplan’s Take
This is a well-documented clinical case, and the interventional management was textbook. The serial ECGs, OCT imaging, and angiographic findings are genuinely instructive for recognizing Wellens syndrome in a younger patient. Where I part ways with the authors is in their framing. Calling this “cannabis-induced” in the title does a disservice to the complexity of what they actually found. The OCT showed lipid-rich plaque, meaning this patient had established atherosclerotic disease. He smoked tobacco for 15 years. His blood pressure at presentation was dangerously high. Any one of these factors could account for the acute event, and attributing it to cannabis specifically requires evidence this report simply cannot provide.
When patients who use cannabis ask me whether it could cause a heart attack, I tell them the honest truth: we do not yet have definitive evidence, but there are concerning signals, and the safest approach is to minimize cardiovascular risk wherever possible. In my practice, I assess every cannabis-using patient for concurrent tobacco use, metabolic risk factors, and blood pressure. I counsel cessation of combustible products first and foremost, because the tobacco co-exposure in cases like this one is never a minor detail. I use cases like this to motivate risk-factor modification, not to assign blame to a single substance.
Clinical Perspective
This case report sits at the earliest, most preliminary stage of the research arc connecting cannabis use to acute coronary events. It joins a small but growing collection of anecdotal reports describing ACS in young cannabis users, including work cited by Mittleman, Desai, and Ladha. What it confirms is that Wellens syndrome can present in young adults without traditional risk factor profiles and that clinicians should maintain high suspicion for critical LAD lesions when this ECG pattern appears, regardless of age. What it does not and cannot confirm is that cannabis caused or independently contributed to this patient’s event. The presence of extensive lipid-rich plaque on OCT demonstrates that this was not a drug-triggered vasospasm on a clean artery; it was an acute thrombotic event on a chronically diseased vessel.
For clinicians managing young patients who use cannabis, the pharmacological considerations are nuanced. THC activates CB1 receptors, which in preclinical models promote vasoconstriction and platelet aggregation, but translating these findings to individual clinical scenarios remains speculative. Cannabis may also interact with antiplatelet agents through cytochrome P450 pathways, though clinical data on this are sparse. The most actionable recommendation from this case is straightforward: in any young patient presenting with chest pain and a history of cannabis use, obtain serial ECGs with close attention to dynamic T-wave changes, and do not allow the patient’s age to delay angiographic evaluation when Wellens pattern is identified.
Study at a Glance
| Study Type | Single-patient case report with narrative literature review |
| Population | 30-year-old male with 15-year daily cannabis-tobacco co-use |
| Intervention | OCT-guided PCI with 5.0×18 mm Xience Skypoint drug-eluting stent |
| Comparator | None |
| Primary Outcomes | Successful revascularization with TIMI 3 flow; clinical stabilization |
| Sample Size | One patient |
| Journal | JACC: Case Reports |
| Year | 2025 |
| DOI or PMID | DOI: 10.1016/j.jaccas.2025.103127 |
| Funding Source | Not reported |
What Kind of Evidence Is This
This is a peer-reviewed, open-access case report describing a single patient’s clinical course with supporting imaging and laboratory data, accompanied by a narrative discussion citing external literature. Case reports occupy the lowest tier of the clinical evidence hierarchy. They are hypothesis-generating, not hypothesis-confirming. The single most important inference constraint this design imposes is that no causal attribution, statistical inference, or generalization to other patients is possible from this observation alone.
How This Fits With the Broader Literature
This case joins a body of anecdotal and observational literature suggesting a possible link between cannabis use and acute cardiovascular events, particularly in younger populations. Mittleman et al. (2001) found a transiently elevated risk of myocardial infarction in the hour following cannabis use, while Desai et al. (2018) identified higher rates of ACS hospitalization among cannabis users in a large administrative database. However, these studies share the limitation of inadequate confounder control, particularly for concurrent tobacco use. The current case adds OCT-level mechanistic detail, showing that the acute event occurred on established atherosclerotic plaque rather than representing isolated vasospasm, which challenges the simpler mechanistic narratives sometimes invoked in the cannabis-cardiovascular literature. Systematic epidemiological studies with rigorous confounder adjustment, ideally separating combustible from non-combustible cannabis delivery methods, remain the critical next step.
Common Misreadings
The most likely overinterpretation of this report is accepting its title at face value and concluding that cannabis caused this patient’s myocardial infarction. The causal language in the title, “Cannabis-Induced Wellens Syndrome,” is not supported by the evidence presented. A 15-year history of tobacco co-use, severely elevated blood pressure, thrombocytosis, and the presence of established lipid-rich atherosclerotic plaque all represent independent and well-established risk factors for acute coronary syndrome. No cannabis-specific biomarkers were measured, and no statistical method exists within a single-case design to isolate the contribution of one exposure from another. This case should be read as a signal worth investigating, not as proof of a causal relationship.
Bottom Line
This case report provides a well-documented example of Wellens syndrome in a young patient and demonstrates appropriate invasive management with excellent procedural outcome. It adds to the growing anecdotal literature suggesting cannabis may play a role in acute coronary events in young adults. However, it cannot establish causation due to its single-case design and multiple uncontrolled confounders, most notably concurrent long-term tobacco use. It should prompt clinical vigilance and further research, not causal claims or policy conclusions.
Frequently Asked Questions
Does this case prove that cannabis causes heart attacks?
No. A single case report cannot prove causation under any circumstances. This patient had multiple other risk factors, including 15 years of tobacco smoking and very high blood pressure at the time of his event. The report raises a question worth studying in larger populations but does not answer it.
What is Wellens syndrome and why is it dangerous?
Wellens syndrome is a specific pattern of T-wave changes on an ECG that signals critical narrowing of the proximal left anterior descending artery, the vessel supplying the largest portion of the heart’s front wall. If unrecognized and untreated, it can progress to a massive anterior wall heart attack. It is particularly important because it can appear when the patient is chest-pain free, leading clinicians to underestimate its severity.
Should I stop using cannabis because of this report?
This single case should not be the basis for individual medical decisions about cannabis use. However, the broader literature does raise concerns about cardiovascular risk with cannabis, especially when combusted or combined with tobacco. Patients with any cardiovascular risk factors should discuss their cannabis use honestly with their physician so that personalized risk assessment can be performed.
Is the risk from cannabis or from smoking it with tobacco?
This is one of the most important unanswered questions in the field. In this case, the patient mixed cannabis with tobacco in every cigarette for 15 years, making it impossible to separate the effects of each substance. Tobacco is a firmly established cause of atherosclerosis and acute coronary events. Until studies adequately control for tobacco co-use and compare different cannabis delivery methods, the independent cardiovascular risk of cannabis remains uncertain.
What did the OCT imaging reveal about the underlying cause?
Optical coherence tomography showed extensive lipid-rich atherosclerotic plaque with an acute red thrombus in the proximal LAD artery. This is significant because it indicates the patient had pre-existing chronic arterial disease, not simply an acute drug-triggered spasm on a healthy vessel. The acute event was a blood clot forming on top of an already diseased artery, which is the same mechanism seen in typical heart attacks regardless of cannabis exposure.
References
- Boukili I, et al. Cannabis-Induced Wellens Syndrome in a Young Patient: A Case Report. JACC: Case Reports. 2025. DOI: 10.1016/j.jaccas.2025.103127.
- Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805-2809. DOI
Have thoughts on this? Share it:
